Pharmacyclics Inc. is a pharmaceutical company developing products to improve upon therapeutic approaches to cancer, atherosclerosis and retinal disease. The company''s products are ring-shaped small molecules called texaphyrins. These patented agents are derived from Pharmacyclics'' versatile technology platform for designing and synthesizing energy-potentiating drugs. The texaphyrins localize in cancer cells, atherosclerotic plaque and neovasculature, where they can be activated by forms of energy, including X-rays and light to reduce diseased tissue.